Cardiovascular Diseases Clinical Trial
The study has two objectives/aims:
Aim 1: To test the efficacy of the intervention among adult smokers with cardiovascular
disease, pulmonary disease and diabetes mellitus related illnesses (later modified to
Chinese adults with and without diseases); and
Aim 2: To examine a set of measures (background, general health, psychosocial, and smoking
process) that are associated with smoking cessation at 6 and 12 months
BACKGROUND:
Studies of smoking cessation intervention among hospitalized patients with CVD and pulmonary
disease produced varying cessation rates, ranging from 20 to 51% among patients with
pulmonary disease, from 22 to 71% among survivors of coronary disease and as much as 80%
among lung cancer patients (3-8). Recently published Treating Tobacco Use and Dependence
Clinical Practice Guideline (1) provides detailed evaluation and synthesis of evidence-based
components of effective smoking cessation interventions and summary results for selected
treatment modalities are presented in Table 1. Face-to-face counsel, strong advice from
physician or nurse, the number of reinforcing sessions and duration of these sessions were
related to success (9). Compared to no treatment, estimated abstinence rates for treatment
modalities ranged from 10.2% to 26.5%. Thus, use of combination treatment modalities in
smoking cessation intervention is expected to result in higher abstinence rate.
The proposed four-year prospective, randomized clinical trial with 12 months follow-up, will
test the efficacy of a culturally and linguistically tailored physician directed, nurse
managed, smoking cessation and relapse prevention intervention among Chinese smokers. The
study has two aims: 1) To test the efficacy of the intervention among smokers; and 2) To
examine a set of measures (background, general health, psychosocial, and smoking process)
that are associated with smoking cessation at 6 and 12 months. Subjects who smoked in the 3
months prior to admission at 6 San Francisco Bay Area hospitals (1 university, 4 private and
1 county) will be screened, recruited and randomized to one of two interventions: a)
Intensive [n=190] (physician advice, bedside counseling with a family member, 5 telephone
contacts within 90 days, with nicotine replacement therapy and one repeat relapse counseling
with 1 more telephone contact for relapsers). b) Minimal [n=190] (physician advice and a
self-help manual). Random assignment will be stratified by recruitment site, gender and
disease category. Primary outcomes include biochemically confirmed abstinence and quit
attempts at 6 and 12 months. Power calculation is based on 15% difference in abstinence
rates between the two intervention groups. The findings from this propose study will yield
significant knowledge for effectively treating Chinese smokers and will provide insight into
treatment for smokers of other racial and ethnic minorities that is likely to have
significant public health impact by reducing health disparities among US sub-populations.
DESIGN NARRATIVE:
A prospective, randomized clinical trial with 12-month follow-up linguistically tailored,
nurse-managed smoking cessation and relapse prevention trial. It involves several stages in
the study:
Stage 1: Recruitment - verify eligibility criteria and making phone appointment for
face-to-face baseline interview and individualized counseling session.
Stage 2: Baseline face-to-face interview either in a hospital setting for inpatients, or in
an office setting for those who were not inpatients - explain study, obtained informed
consent, conducting baseline survey and randomized patients into one of two research arms:
Intensive or minimal. Intensive patients will receive a specific set of interventions and
asked to contract a quit date, whereas minimal subjects will receive the usual care and
advice to quit from the research staff and their physicians.
Stage 3: For subjects randomized to the intensive group, they will receive a set of
intervention support phone calls for their quit-smoking efforts.
Stage 4: Outcome Measurement - All subjects will receive 6- and 12-month phone calls and
saliva samples will be collected to verify non-smoking status. At six months - interim
outcome, at 12 months - final outcome measurement.
Procedures
Cognitive Pretest:
We conducted pretest of the translated materials using individual interviews to ascertain
their face validity. Participants for the cognitive pretest were either bilingual or fluent
in either English or Chinese. These participants will include both current and recent
ex-smokers from the community who speak either Mandarin or Cantonese (the two most commonly
spoken Chinese dialects).
Intervention:
Participants assigned to the minimal intervention group will receive physician advice and a
standard self-help manual, either an English version of "Freedom From Smoking" from the
American Lung Association (ALA), or a Chinese version "Victory over Smoking," (see
attached). The physician advice consists of a strong message urging the patient to quit
smoking (see attached). Physicians will be prompted to deliver a 1- to 2-minute unequivocal
scripted message about the necessity to quit smoking. For the inpatients, a 1-page prototype
Physician Advice Statement will be placed in the progress notes section of the patient's
medical record to serve as a physician reminder. For the outpatients, if the first
counseling session is done outside of the physician's office setting, the 1-page prototype
will be faxed to the physician's office to notify the physician and to remind them to
counsel the study subjects. If the counseling is done in the physician's office, the 1-page
prototype will be given directly to the patients physician or be placed inside the office
chart in his absence.
Participants in the intensive group will receive the nurse- or health educator-managed
smoking cessation and relapse prevention intervention. The intensive intervention has two
periods: initial counseling session and follow-up phone support.
Initial Counseling Session - Patients in the intensive group will receive the scripted
physician advice as well as an endorsement from their physicians about the nurse/health
educator-managed smoking cessation intervention. A nurse/health educator-mediated behavioral
counseling will be provided after obtaining the baseline smoking history and determining
self-efficacy for smoking cessation. The 60- to 90-minute nurse/patient educator-managed
intervention includes components of patient education, skill building and relapse prevention
counseling. During this session, the patient will be given individually-tailored counseling
based on his/her baseline assessment information. They will also be given a 20-minute
smoking cessation video in Chinese, a Chinese workbook Victory over Smoking self-help
manual, based on the Freedom From Smoking workbook from the American Lung Association, and a
15-minute relaxation audiotape in Chinese.
Although the primary focus of the intervention is a cognitive behavioral intervention,
nicotine replacement therapy (NRT) will be offered to patients who do not have medical
contraindications to the NRT and: a) meet the criteria for nicotine dependency; or b) are
noted by the nurses to have severe withdrawal symptoms (inpatients) or self-report severe
withdrawal symptoms during previous quit attempts,; c) relapse after the initial counseling;
and d) smoke more than 10 cigarettes a day.
For patients in either group who have been smoking within the 7 days prior to the time of
the interview, 2-3 cc of saliva will be collected from them for studying the metabolic rate
of cotinine.
Patients will be offered NRT by trained nurse/health educators, in the form of gum
(Nicorette 2 or 4 mg) or patch (Nicoderm 14 or 21 mg), depending on patients' preference. We
will obtain the approval from each subject's physician before providing NRT. Upon physician
consent, patients will be instructed in the correct use of nicotine patch or gum by
nurses/health educators using an 8-week protocol for both the nicotine patch and gum) [see
NRT protocol].
Post-Counseling Period (from 2 to 90 days) - During this period, the nurses/health educators
will contact patients in the intensive group beginning 48 hours post discharge for the
inpatients, and 48 hours post patients' quit dates for the outpatients. Additional calls are
made at 7-, 21-, 45- and 90-day intervals during the period of greatest risk for relapse
(9). Reinforcements for proper nutrition, physical activity and enlisting support from
family members and friends will be provided during each 10-minutes telephone follow-up
contact. If the subjects relapse during the first 90-day period of enrollment (identified
through scheduled telephone calls by nurses/ health educators), they will be offered one
additional intervention telephone call. The purpose of this call is to review the smoking
cessation materials that had been originally presented to the subject, to continue problem
solving with the subject regarding high-risk situations that led to relapse, and to
reinforce the importance of quitting smoking permanently.
The primary focus of our intervention is in cognitive behavioral intervention. Nicotine
replacement therapy is only one component of the intensive intervention. Because NRT is
considered a standard of care, we are not proposing to withhold NRT but rather will not
offer the medication as part of the minimal intervention. Regardless of the intervention
arms, participants will be able to take NRT either on their own or as prescribed by their
clinicians. The nurse/health educator will record the use of NRT among all the other
participants who are treated with NRT.
Intervention Follow-up Assessments:
After the intervention, all subjects will be reassessed by scripted telephone interviews at
6 and 12 months (see attached). Each telephone call will take approximately 10 minutes.
Nurses/health educators will be blinded to group assignment as they made follow-up calls.
Initial questions assess smoking status and categorize each subject into one of three
categories: nonsmoker (had not smoked since the initial counseling session or the last
telephone call), relapser (had smoked since the initial counseling session or the last
telephone call but not on a continuous basis), or continuous smoker (had smoked daily for
the past 7 days). After each assessment, a saliva sample collection kit will be mailed out
to the non-smoking participants with instructions and a postage-paid envelope for return.
Participants who have not returned their cotinine within 15 days will be contacted by
telephone.
;
Allocation: Randomized, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|